Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | STAR0602 |
Synonyms | |
Therapy Description |
STAR0602 is a bifunctional antibody-fusion molecule expressing the b6 and b10 regions of the T cell receptor, which potentially induces tumor regression (Eur J Cancer 2022 Vol 174, Suppl 1:S5). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
STAR0602 | STAR-0602|STAR 0602 | STAR0602 is a bifunctional antibody-fusion molecule expressing the b6 and b10 regions of the T cell receptor, which potentially induces tumor regression (Eur J Cancer 2022 Vol 174, Suppl 1:S5). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05592626 | Phase Ib/II | STAR0602 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001) | Recruiting | USA | FRA | ESP | CAN | 0 |